Index to Volume 28
Index au volume 28

The Journal of Psychiatry & Neuroscience is indexed according to the medical subject headings established by the National Library of Medicine, US National Institutes of Health.

The title for each article is followed by a code that designates the article’s category. The categories used in this volume are listed below.

La Revue de psychiatrie & de neuroscience est indexée par vedette-matière selon la nomenclature de la National Library of Medicine des National Institutes of Health américains.

Chaque titre d’article est suivi d’un code indiquant à quelle catégorie l’article appartient. Les catégories utilisées dans ce volume sont les suivantes :

- A -
  
  Acetylcholine
  Correlates of response to acetylcholinesterase inhibitor therapy in Alzheimer’s disease (Lanctôt and others) (Rev) 13
  Spontaneously hypertensive rats: further evaluation of age-related memory performance and cholinergic marker expression (Hernandez and others) (Res) 197

  Adverse drug reaction reporting systems
  A review of olanzapine-associated toxicity and fatality in overdose (Chue and Singer) (Rev) 253

  Aggression
  The 26th Annual Meeting of the Canadian College of Neuropsychopharmacology, Montréal, Quebec, Canada, June 1–4, 2003 (Leyton and others) (CCNP) 468
  What is a recommended treatment for aggression in a patient with schizophrenia? (Gobbi and Debonnel) (Psychopharm) 320

  Aging
  Spontaneously hypertensive rats: further evaluation of age-related memory performance and cholinergic marker expression (Hernandez and others) (Res) 197

  Agmatine
  Imidazoline binding sites on receptors and enzymes: Emerging targets for novel antidepressant drugs? (Holt) (E) 409

  Alcohol drinking
  The role of GABA, receptors in mediating the effects of alcohol in the central nervous system (Davies) (Rev) 263
  Substance use and cognition in early psychosis (Fencer and Addington) (Res) 48

  Alcoholism
  The 26th Annual Meeting of the Canadian College of Neuropsychopharmacology, Montréal, Quebec, Canada, June 1–4, 2003 (Leyton and others) (CCNP) 468
  The role of GABA, receptors in mediating the effects of alcohol in the central nervous system (Davies) (Rev) 263
  What treatment options exist for alcohol abuse? (Dongier) (Psychopharm) 80

  Alleles
  Dopamine genes and attention-deficit hyperactivity disorder: a review (DiMaio and others) (Rev) 27

Alzheimer disease
The 26th Annual Meeting of the Canadian College of Neuropsychopharmacology, Montréal, Quebec, Canada, June 1–4, 2003 (Leyton and others) (CCNP) 468
Buspirone for anxiety and agitation in dementia (Cooper) (L) 469
Correlates of response to acetylcholinesterase inhibitor therapy in Alzheimer’s disease (Lanctôt and others) (Rev) 13

Amine oxidase (copper-containing)
Imidazoline binding sites on receptors and enzymes: Emerging targets for novel antidepressant drugs? (Holt) (E) 409

Amygdala
Cholecystokinin receptor subtypes: role in the modulation of anxiety-related and reward-related behaviours in animal models (Rotzinger and Vaccarino) (Rev) 171

Amyloid beta-protein precursor
Correlates of response to acetylcholinesterase inhibitor therapy in Alzheimer’s disease (Lanctôt and others) (Rev) 13

Anorexia nervosa
The 26th Annual Meeting of the Canadian College of Neuropsychopharmacology, Montréal, Quebec, Canada, June 1–4, 2003 (Leyton and others) (CCNP) 468

Antidepressive agents
Antidepressants and suicide: risk–benefit conundrums (Healy and Whitaker) (Debate) 331
Hypothalamic-pituitary-thyroid system activity during lithium augmentation therapy in patients with unipolar major depression (Bschor and others) (Brief) 210
Imidazoline binding sites on receptors and enzymes: Emerging targets for novel antidepressant drugs? (Holt) (E) 409
Manic-switch induced by fluvoxamine in abstinent pure methamphetamine abusers (Wan and others) (L) 134
Mirtazapine for treatment-resistant depression: a preliminary report (Wan and others) (Brief) 55
Suicidality with selective serotonin reuptake inhibitors: Valid claim? (Lapierre) (Debate) 340
Treating mood disorders (Joffe) (E) 9

Antipsychotic agents
The 26th Annual Meeting of the Canadian College of Neuropsychopharmacology, Montréal, Quebec, Canada, June 1–4, 2003 (Leyton and others) (CCNP) 468
Acetylcholine genes and post-synaptic nicotinic receptor expression in the hypothalamic-pituitary-thyroid system in patients with schizophrenia (Singh and others) (Res) 39
Effect of buspirone on peripheral dopamine-like and serotonin receptors in patients with schizophrenia (Singh and others) (Res) 39
Interactions between the cytochrome P450 system and the second-generation antipsychotics (Prior and Baker) (Rev) 99
Neurotransmitter interactions in psychotropic drug action: beyond dopamine and serotonin (Greenshaw) (E) 247
A review of olanzapine-associated toxicity and fatality in overdose (Chue and Singer) (Rev) 253
Tardive dystonia and its treatment (Rosebush and Mazurek) (Psychopharm) 240
Understanding antipsychotic “atypicality”: a clinical and pharmacological moving target (Remington) (Rev) 275

Attention deficit disorder with hyperactivity
The 26th Annual Meeting of the Canadian College of Neuropsychopharmacology, Montréal, Quebec, Canada, June 1–4, 2003 (Leyton and others) (CCNP) 468
Dopamine genes and attention-deficit hyperactivity disorder: a review (DiMaio and others) (Rev) 27

Auditory pathways
Brain modules of hallucination: an analysis of multiple cases of lesions (Braun and others) (Rev) 432

Autistic disorder
The 26th Annual Meeting of the Canadian College of Neuropsychopharmacology, Montréal, Quebec, Canada, June 1–4, 2003 (Leyton and others) (CCNP) 468

- B -

Beclomethasone
Beclomethasone-induced vasoconstriction in women with major depressive disorder (Coupland and others) (Res) 364

Behavior, addictive
The 26th Annual Meeting of the Canadian College of Neuropsychopharmacology, Montréal, Quebec, Canada, June 1–4, 2003 (Leyton and others) (CCNP) 468

Behavioral research
Cholecystokinin receptor subtypes: role in the modulation of anxiety-related and reward-related behaviours in animal models (Rotzinger and Vaccarino) (Rev) 171

Behavioral symptoms
Correlates of response to acetylcholinesterase inhibitor therapy in Alzheimer’s disease (Lancot and others) (Rev) 13

Binding sites
Imidazoline binding sites on receptors and enzymes: Emerging targets for novel antidepressant drugs? (Holl) (E) 409

Biogenic amines
Imidazoline binding sites on receptors and enzymes: Emerging targets for novel antidepressant drugs? (Holl) (E) 409

Biotransformation
Interactions between the cytochrome P450 system and the second-generation antipsychotics (Prior and Baker) (Rev) 99

Bipolar disorder
Effects of dextroamphetamine, lithium chloride, sodium valproate and carbamazepine on intraplatelet Ca2+ levels (Ulrich and others) (Res) 115

Tardive dystonia and its treatment (Rosebush and Mazurek) (Psychopharm) 240

Thyroid hormone treatment for lithium-induced thyroid dysfunction in mood disorder (Ramasubbu) (L) 134

Treating mood disorders (Joffe) (E) 9

Blood platelets
Effect of loxapine on peripheral dopamine-like and serotonin receptors in patients with schizophrenia (Singh and others) (Res) 39

Effects of dextroamphetamine, lithium chloride, sodium valproate and carbamazepine on intraplatelet Ca2+ levels (Ulrich and others) (Res) 115

Book review
Foundations in Social Neuroscience (Young and Moskowitz) (Book) 375

Handbook and Transcranial Magnetic Stimulation (Nahas) (Book) 373

Mood Disorders in Women (Calhoun) (Book) 139

Psychiatric Medications for Older Adults: The Concise Guide (Sadavoy) (Book) 140

Psychiatry in Canada: Fifty Years (Joffe) (Book) 377

Psychiatry in the Elderly (Le K and Le Clair) (Book) 376

The Psychopharmacology of Herbal Medicine: Plant Drugs That Alter Mind, Brain and Behavior (Couts) (Book) 300

Botulinum toxin type A
Tardive dystonia and its treatment (Rosebush and Mazurek) (Psychopharm) 240

Brain
Anterior cingulate dysfunction: Implications for psychiatric disorders? (Yücel and others) (Comm) 350

Brain modules of hallucination: an analysis of multiple cases of lesions (Braun and others) (Rev) 432

Brain mapping
The 26th Annual Meeting of the Canadian College of Neuropsychopharmacology, Montréal, Quebec, Canada, June 1–4, 2003 (Leyton and others) (CCNP) 468

Brief psychiatric rating scale
Effect of loxapine on peripheral dopamine-like and serotonin receptors in patients with schizophrenia (Singh and others) (Res) 39

Bromocriptine
What treatment options exist for alcohol abuse? (Dongier) (Psychopharm) 80

Bulimia
The 26th Annual Meeting of the Canadian College of Neuropsychopharmacology, Montréal, Quebec, Canada, June 1–4, 2003 (Leyton and others) (CCNP) 468

Buspirone
Buspirone for anxiety and agitation in dementia (Cooper) (L) 469

What treatment options exist for alcohol abuse? (Dongier) (Psychopharm) 80

- C -

Calcium
Effects of dextroamphetamine, lithium chloride, sodium valproate and carbamazepine on intraplatelet Ca2+ levels (Ulrich and others) (Res) 115

Cannabis
Substance use and cognition in early psychosis (Pencer and Addington) (Res) 48

Carbamazepine
Effects of dextroamphetamine, lithium chloride, sodium valproate and carbamazepine on intraplatelet Ca2+ levels (Ulrich and others) (Res) 115

Case–control studies
Dopamine genes and attention-deficit hyperactivity disorder: a review (DiMaio and others) (Rev) 27

Catecholamines
A new method for rapidly and simultaneously decreasing serotonin and catecholamine synthesis in humans (Leyton and others) (Brief) 464

Central nervous system
The 26th Annual Meeting of the Canadian College of Neuropsychopharmacology, Montréal, Quebec, Canada, June 1–4, 2003 (Leyton and others) (CCNP) 468

Cerebral cortex
Anterior cingulate dysfunction: Implications for psychiatric disorders? (Yücel and others) (Comm) 350

China
Smoking and tardive dyskinesia: lack of involvement of the CYP1A2 gene (Chong and others) (Res) 185

Cholecystokinin
Cholecystokinin receptor subtypes: role in the modulation of anxiety-related and reward-related behaviours in animal models (Rotzinger and Vaccarino) (Rev) 171

Cholesterol
Pentagastrin-induced release of free fatty acids in healthy volunteers and patients with panic disorder: effect of pretreatment with ethylid estradiol (Morrow and others) (Res) 127

Cholinesterase inhibitors
Correlates of response to acetylcholinesterase inhibitor therapy in Alzheimer’s disease (Lancot and others) (Rev) 13

Chronic disease
Mirtazapine for treatment-resistant depression: a preliminary report (Wan and others) (Brief) 55

Clonidine
Imidazoline binding sites on receptors and enzymes: Emerging targets for novel antidepressant drugs? (Holl) (E) 409
Cognitive disorders
Substance use and cognition in early psychosis (Pencer and Addington) (Res) 48

Cytochrome P-450 CYP1A2
Smoking and tardive dyskinesia: lack of involvement of the CYP1A2 gene (Chong and others) (Res) 185

Cytochrome P-450 enzyme system
Interactions between the cytochrome P450 system and the second-generation antipsychotics (Prior and Baker) (Rev) 99

- D -

Dementia
Buspirone for anxiety and agitation in dementia (Cooper) (L) 469
Correlates of response to acetylcholinesterase inhibitor therapy in Alzheimer’s disease (Lancot and others) (Rev) 13

Depression
The 26th Annual Meeting of the Canadian College of Neuropsychopharmacology, Montréal, Québec, Canada, June 1–4, 2003 (Leyton and others) (CCNP) 468
Manic-switch induced by fluvoxamine in abstinent pure methamphetamine abusers (Won and others) (L) 134

Depressive disorder
Beclomethasone-induced vasocostriction in women with major depressive disorder (Coupland and others) (Res) 364
Effectiveness and outcome predictors of long-term lithium prophylaxis in unipolar major depressive disorder (Baethge and others) (Res) 355
Hypothalamic-pituitary-thyroid system activity during lithium augmentation therapy in patients with unipolar major depression (Bschor and others) (Brief) 210
Mirtazapine for treatment-resistant depression: a preliminary report (Wan and others) (Brief) 55
Repetitive transcranial magnetic stimulation for depression (Cooke) (Psychopharm) 400
Treating mood disorders (Joffe) (E) 9

Dextroamphetamine
Effects of dextroamphetamine, lithium chloride, sodium valproate and carbamazepine on intraplatelet Ca2+ levels (Ulrich and others) (Res) 115

Diagnosis
The prodromal stage of psychotic illness: Observation, detection or intervention? (Addington) (Comm) 93

Diazepam
Effects of diazepam on facial emotion recognition (Coupland and others) (Res) 452

Disease
Lifestyle drugs, mood, behaviour and cognition (Young) (E) 87

Disease progression
The prodromal stage of psychotic illness: Observation, detection or intervention? (Addington) (Comm) 93

Dopamine
Cholecystokinin receptor subtypes: role in the modulation of anxiety-related and reward-related behaviours in animal models (Rotzinger and Vaccarino) (Rev) 171
Dopamine genes and attention-deficit hyperactivity disorder: a review (DiMaio and others) (Rev) 27
Neurotransmitter interactions in psychotropic drug action: beyond dopamine and serotonin (Greenshaw) (E) 247
A new method for rapidly and simultaneously decreasing serotonin and catecholamine synthesis in humans (Leyton and others) (Brief) 464
Understanding antipsychotic “atypicality”: a clinical and pharmacological moving target (Remington) (Rev) 275

Dreams
Brain modules of hallucination: an analysis of multiple cases of lesions (Braun and others) (Rev) 432

Drug interactions
Interactions between the cytochrome P450 system and the second-generation antipsychotics (Prior and Baker) (Rev) 99

Drug resistance
Mirtazapine for treatment-resistant depression: a preliminary report (Wan and others) (Brief) 55

Drug therapy
The 26th Annual Meeting of the Canadian College of Neuropsychopharmacology, Montréal, Québec, Canada, June 1–4, 2003 (Leyton and others) (CCNP) 468
Brand versus generic medications: the money, the patient and the research (Blier) (E) 167
Effects of dextroamphetamine, lithium chloride, sodium valproate and carbamazepine on intraplatelet Ca2+ levels (Ulrich and others) (Res) 115
Lifestyle drugs, mood, behaviour and cognition (Young) (E) 87
Neurotransmitter interactions in psychotropic drug action: beyond dopamine and serotonin (Greenshaw) (E) 247

Drug therapy, combination
Effectiveness and outcome predictors of long-term lithium prophylaxis in unipolar major depressive disorder (Baethge and others) (Res) 355
Hypothalamic-pituitary-thyroid system activity during lithium augmentation therapy in patients with unipolar major depression (Bschor and others) (Brief) 210

Drug toxicity
Mirtazapine for treatment-resistant depression: a preliminary report (Wan and others) (Brief) 55
A review of olanzapine-associated toxicity and fatality in overdose (Chue and Singer) (Rev) 253

Dyskinesias
Smoking and tardive dyskinesia: lack of involvement of the CYP1A2 gene (Chong and others) (Res) 185

Dystonia
Tardive dystonia and its treatment (Rosebush and Mazurek) (Psychopharm) 240

- E -

Eating disorders
The 26th Annual Meeting of the Canadian College of Neuropsychopharmacology, Montréal, Québec, Canada, June 1–4, 2003 (Leyton and others) (CCNP) 468

Editorial policies
Peer review of manuscripts: theory and practice (Young) (E) 327

Electroconvulsive therapy
Repetitive transcranial magnetic stimulation for depression (Cooke) (Psychopharm) 400

Electroencephalography
Correlates of response to acetylcholinesterase inhibitor therapy in Alzheimer’s disease (Lancot and others) (Rev) 13

Emotions
Effects of diazepam on facial emotion recognition (Coupland and others) (Res) 452
Lifestyle drugs, mood, behaviour and cognition (Young) (E) 87

Epidemiology
Antidepressants and suicide: risk–benefit conundrums (Healy and Whitaker) (Debate) 331
Suicidality with selective serotonin reuptake inhibitors: Valid claim? (Lapierre) (Debate) 340

Epilepsy
Brain modules of hallucination: an analysis of multiple cases of lesions (Braun and others) (Rev) 432

Estradiol
The 26th Annual Meeting of the Canadian College of Neuropsychopharmacology, Montréal, Québec, Canada, June 1–4, 2003 (Leyton and others) (CCNP) 468
Ethanol
The role of GABA<sub>A</sub> receptors in mediating the effects of alcohol in the central nervous system (Davies) (Rev) 263

Ethinyl estradiol
Pentagastrin-induced release of free fatty acids in healthy volunteers and patients with panic disorder: effect of pretreat-ment with ethinyl estradiol (Morrow and others) (Res) 127

Fetal alcohol syndrome
The role of GABA<sub>A</sub> receptors in mediating the effects of alcohol in the central nervous system (Davies) (Rev) 263

Fura-2
Effects of dextroamphetamine, lithium chloride, sodium valproate and carbamazepine on intraplatelet Ca<sup>2+</sup> levels (Ulrich and others) (Res) 115

Gamma-aminobutyric acid
Effects of diazepam on facial emotion recognition (Coupland and others) (Res) 452

Gene expression
The role of GABA<sub>A</sub> receptors in mediating the effects of alcohol in the central nervous system (Davies) (Rev) 263

Gene expression
The 26th Annual Meeting of the Canadian College of Neuropsychopharmacology, Montréal, Quebec, Canada, June 1–4, 2003 (Leyton and others) (CCNP) 468

Genetic predisposition to disease
Dopamine genes and attention-deficit hyperactivity disorder: a review (D'Maio and others) (Rev) 27
Molecular genetics of schizophrenia: a critical review (Berry and others) (Rev) 415
The role of GABA<sub>A</sub> receptors in mediating the effects of alcohol in the central nervous system (Davies) (Rev) 263
Smoking and tardive dyskinesia: lack of involvement of the CYPIA2 gene (Chong and others) (Res) 185

Genetics, behavioral
Molecular genetics of schizophrenia: a critical review (Berry and others) (Rev) 415

Glucocorticoid
Beclohexastone-induced vasoconstriction in women with major depressive disorder (Coupland and others) (Res) 364

Glutamic acid
Understanding antipsychotic “atypicality”: a clinical and pharmacological moving target (Remington) (Rev) 275

Gyrus cinguli
Anterior cingulate dysfunction: Implications for psychiatric disorders? (Yücel and others) (Comm) 350

Hallucinations
Brain modules of hallucination: an analysis of multiple cases of lesions (Braun and others) (Rev) 432
Left with the voices or hearing right? Laterization of auditory verbal hallucinations in schizophrenia (Sommer and others) (L) 217; Reply (Stip and Ait Bentaleb) (L) 218

Haloperidol
Actigraphic measurement of the effects of single-dose haloperidol and olanzapine on spontaneous motor activity in normal subjects (Kiang and others) (Res) 293

Health services
The University of Ottawa model for obtaining the needed spectrum of psychiatric services: its relevance in the world today (Sarwer-Foner) (CCNP) 136

Hydrocortisone
Beclohexastone-induced vasoconstriction in women with major depressive disorder (Coupland and others) (Res) 364

5-Hydroxytryptophan
Are SAMe and 5-HTP safe and effective treatments for depression? (Young) (Psychopharm) 471

Hypertension
Spontaneously hypertensive rats: further evaluation of age-related memory performance and cholinergic marker expression (Hernandez and others) (Res) 197

Hypothyroidism
Thyroid hormone treatment for lithium-induced thyroid dysfunction in mood disorder (Ramasubbu) (L) 134

Imidazoles
Imidazoline binding sites on receptors and enzymes: Emerging targets for novel antidepressant drugs? (Holt) (E) 409

Ion channel gating
The role of GABA<sub>A</sub> receptors in mediating the effects of alcohol in the central nervous system (Davies) (Rev) 263

Legislation, drug
Lifestyle drugs, mood, behaviour and cognition (Young) (E) 87

Linkage (genetics)
Molecular genetics of schizophrenia: a critical review (Berry and others) (Rev) 415

Lithium carbonate
Effectiveness and outcome predictors of long-term lithium prophylaxis in unipolar major depressive disorder (Baethge and others) (Res) 355
Hypothalamic-pituitary-thyroid system activity during lithium augmentation therapy in patients with unipolar major depression (Bschor and others) (Brief) 210
Thyroid hormone treatment for lithium-induced thyroid dysfunction in mood disorder (Ramasubbu) (L) 134

Lithium chloride
Effects of dextroamphetamine, lithium chloride, sodium valproate and carbamazepine on intraplatelet Ca<sup>2+</sup> levels (Ulrich and others) (Res) 115

Lorazepam
Effect of lorazepam on peripheral dopamine-like and serotonin receptors in patients with schizophrenia (Singh and others) (Res) 39

Magnetic resonance imaging
Neurotransmitter interactions in psychotropic drug action: beyond dopamine and serotonin (Greenshaw) (E) 247

Melatonin
Treatment of primary insomnia with melatonin: a double-blind, placebo-controlled, crossover study (Almeida Montes and others) (Res) 191

Memory disorders
Spontaneously hypertensive rats: further evaluation of age-related memory performance and cholinergic marker expression (Hernandez and others) (Res) 197

Mental disorders
Anterior cingulate dysfunction: Implications for psychiatric disorders? (Yücel and others) (Comm) 350

Mental health services
The University of Ottawa model for obtaining the needed spectrum of psychiatric services: its relevance in the world today (Sarwer-Foner) (CCNP) 136
Meta-analysis
Antidepressants and suicide: risk-benefit conundrums (Healy and Whitaker) (Debate) 331
Dopamine genes and attention-deficit hyperactivity disorder: a review (DiMaio and others) (Rev) 27
Suicidality with selective serotonin reuptake inhibitors: Valid claim? (Lapierre) (Debate) 340

Metabolism
Interactions between the cytochrome P450 system and the second-generation antipsychotics (Prior and Baker) (Rev) 99

Methamphetamine
Manic-switch induced by fluvoxamine in abstinent pure methamphetamine abusers (Won and others) (L) 134

Minisatellite repeats
Dopamine genes and attention-deficit hyperactivity disorder: a review (DiMaio and others) (Rev) 27

Models, animal
Cholecystokinin receptor subtypes: role in the modulation of anxiety-related and reward-related behaviours in animal models (Rotzinger and Vaccarino) (Rev) 171
Spontaneously hypertensive rats: further evaluation of age-related memory performance and cholinergic marker expression (Hernandez and others) (Res) 197

Molecular biology
Dopamine genes and attention-deficit hyperactivity disorder: a review (DiMaio and others) (Rev) 27

Monitoring, ambulatory
Actigraphic measurement of the effects of single-dose haloperidol and olanzapine on spontaneous motor activity in normal subjects (Kiang and others) (Res) 293

Monoamine oxidase
Imidazoline binding sites on receptors and enzymes: Emerging targets for novel antidepressant drugs? (Holt) (E) 409

Mood disorders
The 26th Annual Meeting of the Canadian College of Neuropsychopharmacology, Montréal, Quebec, Canada, June 1–4, 2003 (Leyton and others) (CCNP) 468
Lifestyle drugs, mood, behaviour and cognition (Young) (E) 87
Neurotransmitter interactions in psychotropic drug action: beyond dopamine and serotonin (Greenshaw) (E) 247
Thyroid hormone treatment for lithium-induced thyroid dysfunction in mood disorder (Ramasubbu) (L) 134

Motivation
The 26th Annual Meeting of the Canadian College of Neuropsychopharmacology, Montréal, Quebec, Canada, June 1–4, 2003 (Leyton and others) (CCNP) 468

Motor activity
Actigraphic measurement of the effects of single-dose haloperidol and olanzapine on spontaneous motor activity in normal subjects (Kiang and others) (Res) 293

Movement disorders
Smoking and tardive dyskinesia: lack of involvement of the CYPIA2 gene (Chong and others) (Res) 185

Naltrexone
What treatment options exist for alcohol abuse? (Dongier) (Psychopharm) 80

Neuropsychopharmacology
Imidazoline binding sites on receptors and enzymes: Emerging targets for novel antidepressant drugs? (Holt) (E) 409

Nitric oxide
Plasma nitrate levels in deficit versus non-deficit forms of schizophrenia (Suzuki and others) (Res) 288

Norepinephrine
A new method for rapidly and simultaneously decreasing serotonin and catecholamine synthesis in humans (Leyton and others) (Brief) 464

Nucleus accumbens
Cholecystokinin receptor subtypes: role in the modulation of anxiety-related and reward-related behaviours in animal models (Rotzinger and Vaccarino) (Rev) 171

Olanzapine
Actigraphic measurement of the effects of single-dose haloperidol and olanzapine on spontaneous motor activity in normal subjects (Kiang and others) (Res) 293
A review of olanzapine-associated toxicity and fatality in overdose (Chue and Singer) (Rev) 253

Overdose
A review of olanzapine-associated toxicity and fatality in overdose (Chue and Singer) (Rev) 253

Panic disorder
The 26th Annual Meeting of the Canadian College of Neuropsychopharmacology, Montréal, Quebec, Canada, June 1–4, 2003 (Leyton and others) (CCNP) 468

Pentagastrin
Pentagastrin-induced release of free fatty acids in healthy volunteers and patients with panic disorder: effect of pretreat-ment with ethynyl estradiol (Morrow and others) (Res) 127

Pentotrin
Pentagastrin-induced release of free fatty acids in healthy volunteers and patients with panic disorder: effect of pretreat-ment with ethynyl estradiol (Morrow and others) (Res) 127

Perception
Effects of diazepam on facial emotion recognition (Coupland and others) (Res) 452

Periodicals
Peer review of manuscripts: theory and practice (Young) (E) 327

Phenylalanine
A new method for rapidly and simultaneously decreasing serotonin and catecholamine synthesis in humans (Leyton and others) (Brief) 464

Phosphatidylinositols
Effects of dextroamphetamine, lithium chloride, sodium valproate and carbamazepine on intraplatelet Ca²⁺ levels (Ulrich and others) (Res) 115

Polymorphism, genetics
Dopamine genes and attention-deficit hyperactivity disorder: a review (DiMaio and others) (Rev) 27

Prescriptions, drug
Brand versus generic medications: the money, the patient and the research (Blier) (E) 167

Psychiatric status rating scales
Effect of loxapine on peripheral dopamine-like and serotonin receptors in patients with schizophrenia (Singh and others) (Res) 39
The prodromal stage of psychotic illness: Observation, detection or intervention? (Addington) (Comm) 93

Psychiatry
The University of Ottawa model for obtaining the needed spectrum
Sedative-hypnotics

Triiodothyronine

Treatment outcome

Torticollis

Tomography, emission-computed, single-photon

Thyroid hormones

Thyrotropin

Thyroxine

Tolerance

Tryptophan

Triptamines

Tryptamines

Imidazoline binding sites on receptors and enzymes: Emerging targets for novel antidepressant drugs? (Holt) (E) 409

Brand versus generic medications: the money, the patient and the research (Blier) (E) 167

Is tryptophan a natural hypnotic? (Young) (Psychopharm) 160

A new method for rapidly and simultaneously decreasing serotonin and catecholamine synthesis in humans (Leyton and others) (Brief) 464

Tyrosine

A new method for rapidly and simultaneously decreasing serotonin and catecholamine synthesis in humans (Leyton and others) (Brief) 464

Valproic acid

Effects of dextroamphetamine, lithium chloride, sodium valproate and carbamazepine on intraplatelet Ca2+ levels (Ulrich and others) (Res) 115

Visual pathways

Brain modules of hallucination: an analysis of multiple cases of lesions (Braun and others) (Rev) 432

Authors / Auteurs

Addington J

The prodromal stage of psychotic illness: Observation, detection or intervention? (Comm) 93

Addington J See Pencer A Jt Auth

Adli M See Bschor T Jt Auth

Ait Bentaleb L See Stip E Jt Auth

Aleman A See Sommer IEC Jt Auth

Almeida Montes LG, Ontiveros Uribe MP, Cortés Sotres J, Heinze Martin G

Treatment of primary insomnia with melatonin: a double-blind, placebo-controlled, crossover study (Res) 191

Asghar SJ See Ulrich ML Jt Auth

- B -

Baethge C, Gruschka P, Smolka MN, Berghöfer A, Bschor T, Müller-Oerlinghausen B, Bauer M

Effectiveness and outcome predictors of long-term lithium prophylaxis in unipolar major depressive disorder (Baethge and others) (Res) 355

Baethge C See Bschor T Jt Auth

Baker GB See Prior TJ Jt Auth

Barlas C See Singh AN Jt Auth

Bauer M See Baethge C Jt Auth; Bschor T Jt Auth

Bellavance F See Morrow JD Jt Auth

Benkelfat C See Leyton M Jt Auth

Berghöfer A See Baethge C Jt Auth

Berry N, Jobanputra V, Pal H

Molecular genetics of schizophrenia: a critical review (Rev) 415

Blair RJ See Coupland NJ Jt Auth

Blier P

Brand versus generic medications: the money, the patient and the research (E) 167

Braun CMJ, Dumont M, Duval J, Hamel-Hébert I, Godbout L

Brain modules of hallucination: an analysis of multiple cases of lesions (Rev) 432

- T -

Tacrine

Correlates of response to acetylcholinesterase inhibitor therapy in Alzheimer’s disease (Lanctôt and others) (Rev) 13

Technology, pharmaceutical

Brand versus generic medications: the money, the patient and the research (Blier) (E) 167

Thyroid hormones

Thyroid hormone treatment for lithium-induced thyroid dysfunction in mood disorder (Ramasubbu) (L) 134

Thyroidal hormones

Hyperthyroidism associated with thyroid hormone treatment in patients with unipolar major depression (Bschor and others) (Brief) 210

Thyrotropin

Hypothalamic-pituitary-thyroid system activity during lithium augmentation therapy in patients with unipolar major depression (Bschor and others) (Brief) 210

Thyroxine

Hypothalamic-pituitary-thyroid system activity during lithium augmentation therapy in patients with unipolar major depression (Bschor and others) (Brief) 210

Tomography, emission-computed, single-photon

Correlates of response to acetylcholinesterase inhibitor therapy in Alzheimer’s disease (Lanctôt and others) (Rev) 13

Torticollis

Tardive dystonia and its treatment (Rosebush and Mazeurek) (Psychopharm) 240

Treatment outcome

Antidepressants and suicide: risk–benefit conundrums (Healy and Whitaker) (Debate) 331

Correlates of response to acetylcholinesterase inhibitor therapy in Alzheimer’s disease (Lanctôt and others) (Rev) 13

Effectiveness and outcome predictors of long-term lithium prophylaxis in unipolar major depressive disorder (Baethge and others) (Res) 355

Hypothalamic-pituitary-thyroid system activity during lithium augmentation therapy in patients with unipolar major depression (Bschor and others) (Brief) 210

Mirtazapine for treatment-resistant depression: a preliminary report (Wan and others) (Res) 355

Mirtazapine for treatment-resistant depression: a preliminary report (Wan and others) (Brief) 55

The prodromal stage of psychotic illness: Observation, detection or intervention? (Addington) (Comm) 93

Suicidality with selective serotonin reuptake inhibitors: Valid claim? (Lapierre) (Debate) 340

Suicidality with selective serotonin reuptake inhibitors: Valid claim? (Young) (Psychopharm) 160